ALS TDI will use stocks in mouse models to study knock-down or over-expression of certain genes.
The ALS Therapy Development Institute (ALS TDI) inked a deal with Microbix Biosystems for the manufacture of adenoviral stocks to be tested in the mouse model of amyotrophic lateral sclerosis (ALS).
“The relationship with Microbix will allow the R&D team at the ALS TDI to test dozens of adenoviral constructs to knock down the expression of genes or over-express genes that may impact disease progression in the mouse model of ALS,” says Steve Perrin, CSO at the ALS TDI.
Under the terms of the one-year contract, Microbix will use its technology to produce, purify, and characterize various adenoviruses created to carry therapies to sites of ALS pathology.
